Art. -Nr.: HY-B1005

8-Hydroxyquinoline

(Synonyms: 8-Quinolinol)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

8-Hydroxyquinoline (8-Quinolinol) is a lipophilic metal chelator that can be used as a fungicide .8-Hydroxyquinoline shows the MIC range of 27.56-55.11 μM (4-8 μg/mL) against the clinical isolates of Neisseria gonorrhoeae. 8-Hydroxyquinoline can bind to copper form complexes and transport copper into cells. 8-Hydroxyquinoline increases in the number of micronucleated polychromatic erythrocytes and can also make hair depigmented in mice.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.95%
CAS. Nr.: 148-24-3
Formel: C₉H₇NO
Molecular Weight:145.16

Speicherung:

Store at room temperature 3 years.

In solvent -80°C, 2 years , -20°C, 1 year

8-Hydroxyquinoline Chemical Structure

CAS. Nr.: 148-24-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	31.25 μM Compound: 8HQ	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33453603]
A549	IC₅₀	32.63 μM Compound: 8HQ	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay	[PMID: 33453603]
A549	IC₅₀	6.58 μM Compound: 8HQ	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay	[PMID: 33453603]
FM3A	IC₅₀	2.1 μM Compound: 34	Inhibit growth of FM3A cells by 50% Inhibit growth of FM3A cells by 50%	[PMID: 1732542]
HCT-116	IC₅₀	21.09 μM Compound: 8HQ	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33453603]
HCT-116	IC₅₀	26.3 μM Compound: 8HQ	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay	[PMID: 33453603]
HCT-116	IC₅₀	6 μM Compound: 4	Antiproliferative activity against human HCT116 cells after 72 hrs by Cell Titer-Glo assay Antiproliferative activity against human HCT116 cells after 72 hrs by Cell Titer-Glo assay	[PMID: 28191850]
HCT-116	IC₅₀	7.25 μM Compound: 8HQ	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay	[PMID: 33453603]
HeLa	IC₅₀	>50 μM Compound: 8HQ	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33453603]
HeLa	IC₅₀	>50 μM Compound: 8HQ	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay	[PMID: 33453603]
HeLa	IC₅₀	13.5 μM Compound: HQ	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by resazurin assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by resazurin assay	[PMID: 27191619]
HeLa	IC₅₀	35.65 μM Compound: 8HQ	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay	[PMID: 33453603]
HepG2	IC₅₀	>50 μM Compound: 8HQ	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33453603]
HepG2	IC₅₀	>50 μM Compound: 8HQ	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay	[PMID: 33453603]
HepG2	IC₅₀	32.1 μM Compound: 8HQ	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay	[PMID: 33453603]
KB	IC₅₀	<2.1 μM Compound: 34	Inhibit growth of KB cells by 50% Inhibit growth of KB cells by 50%	[PMID: 1732542]
MCF7	IC₅₀	>50 μM Compound: 8HQ	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33453603]
MCF7	IC₅₀	>50 μM Compound: 8HQ	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay	[PMID: 33453603]
MCF7	IC₅₀	21.06 μM Compound: 8HQ	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay	[PMID: 33453603]
MES-SA	IC₅₀	5.04 μM Compound: 12	Cytotoxicity against human MES-SA cells assessed as cell growth inhibition incubated for 72 hrs by PrestoBlue reagent based cell viability assay Cytotoxicity against human MES-SA cells assessed as cell growth inhibition incubated for 72 hrs by PrestoBlue reagent based cell viability assay	[PMID: 35613553]
MES-SA/Dx5	IC₅₀	3.04 μM Compound: 12	Cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as cell growth inhibition incubated for 72 hrs by PrestoBlue reagent based cell viability assay Cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as cell growth inhibition incubated for 72 hrs by PrestoBlue reagent based cell viability assay	[PMID: 35613553]
PANC-1	IC₅₀	24.52 μM Compound: 8HQ	Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33453603]
PANC-1	IC₅₀	30.44 μM Compound: 8HQ	Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay	[PMID: 33453603]
PANC-1	IC₅₀	7.43 μM Compound: 8HQ	Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay	[PMID: 33453603]
PC-3	IC₅₀	>50 μM Compound: 8HQ	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay	[PMID: 33453603]
PC-3	IC₅₀	14.36 μM Compound: 8HQ	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay	[PMID: 33453603]
PC-3	IC₅₀	32.01 μM Compound: 8HQ	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33453603]
Sf9	IC₅₀	1.27 μM Compound: 21	Inhibition of recombinant full length human N-terminal GST/His6-tagged methionine aminopeptidase 2 expressed in baculovirus infected sf9 cells using methionylprolyl-p-nitroanilide as substrate preincubated for 20 mins followed by substrate addition measur Inhibition of recombinant full length human N-terminal GST/His6-tagged methionine aminopeptidase 2 expressed in baculovirus infected sf9 cells using methionylprolyl-p-nitroanilide as substrate preincubated for 20 mins followed by substrate addition measur	[PMID: 28089350]
Sf9	IC₅₀	5.6 μM Compound: 8-Hydroxy quinoline	Inhibition of human MetAP2 expressed in baculovirus infected Sf9 cells Inhibition of human MetAP2 expressed in baculovirus infected Sf9 cells	[PMID: 20621724]
SW1990	IC₅₀	>50 μM Compound: 8HQ	Cytotoxicity against human SW1990 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay Cytotoxicity against human SW1990 cells assessed as reduction in cell viability measured after 48 hrs in presence of FeCl3 by MTT assay	[PMID: 33453603]
SW1990	IC₅₀	10.23 μM Compound: 8HQ	Cytotoxicity against human SW1990 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay Cytotoxicity against human SW1990 cells assessed as reduction in cell viability measured after 48 hrs in presence of CuCl2 by MTT assay	[PMID: 33453603]
SW1990	IC₅₀	32.1 μM Compound: 8HQ	Cytotoxicity against human SW1990 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human SW1990 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33453603]

In Vitro

8-Hydroxyquinoline (8HQ) (Compd 1) shows cytotoxicity in MRC-5 cells with an IC₅₀ of 6.27 μM^[1].
8-Hydroxyquinoline (8-OHQ) (Compd 1) (mixture of CuCl₂ at 10.0 μM, 1 hour) binds to copper and form complexes can facilitate transport of copper into human breast cancer DCIS cells^[2].
8-Hydroxyquinoline (mixture of CuCl₂ at 1-20 μM; 1 or 8 hour) binds to copper and form complexes induces cell death with a time and dose-dependent manner in DCIS cells^[2].
8-Hydroxyquinoline (mixture of CuCl₂ at 1-5 μM, 2-12 hour) inhibits proteasomal chymotrypsin-like activity^[2].
8-Hydroxyquinoline (0-100 μM, 30 min) acts to inhibit inflammation through inhibition of NO production and iNOS expression through blockade of C/EBPb DNA-binding activity and NF-jB activation in Raw 264.7 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

DCIS cells
Concentration:

1,2.5,5,10,20 μM
Incubation Time:

1 or 8 hour
Result:

Binding to copper and form complexes make the cells rounded up and detached, induces cell death with in a concentration- and time-dependent manner.
8-OHQ- and CQ-Cu, but not mixture of their analogues and Cu, could induce cancer cell death in a concentration- and time-dependent manner.

Western Blot Analysis^[2]

Cell Line:

DCIS cells
Concentration:

1,2.5,5 μM
Incubation Time:

0,2,4,8,12 hours
Result:

Mixture of CuCl₂ inhibited the CT-like activity in a concentration- and time-dependent manner.
Mixture of CuCl₂ decreased proteasomal activity and increased ubquititinated proteins and Bax accumulated in a time-dependent manner.

RT-PCR^[3]

Cell Line:

Lipopolysaccharides (HY-D1056)-stimulated Raw 264.7 cells
Concentration:

25,50,75,100 μM
Incubation Time:

30 min
Result:

Inhibited of LPS-induced NO and iNOS expression.br/> Inhibits transcription of iNOS.
Had not affect phosphorylation of MAPKs.
Inhibited NF-jB-binding activity and C/EBPb-binding activity.

In Vivo

8-Hydroxyquinoline (HOQ) (25-100 mg/kg, i.p.,single dose) results in a significant dose-related increase in the number of micronucleated polychromatic erythrocytes (MPCE) in CD1 mice^[4].
8-Hydroxyquinoline (8-HQ) (0.3%, skin administration, 4 times weekly) causes depigmented hair to grow in patterns which change with time in mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CD1 mice^[4]
Dosage:

25,50,100 mg/kg
Administration:

Intraperitoneal injection (i.p.)
Result:

Resulted in a significant dose-related increase in the number of micronucleated polychromatic erythrocytes (MPCE) at the 24 h samplingtime for all doses tested.

Animal Model:

C57BL mice^[5]
Dosage:

0.3% 4 times weekly
Administration:

Skin administration
Result:

Caused depigmented hair to grow in patterns which change with time.
Sufficiently frequent applications result in virtually complete depigmentation in young adult C57BL female mice, while single application causes isolated bands of depigmented hair.

Chemical Information

CAS. Nr. 148-24-3
Appearance Solid
Molecular Weight 145.16
Formel C₉H₇NO
Color Off-white to light yellow
SMILES

OC1=C2N=CC=CC2=CC=C1
Synonyms

8-Quinolinol
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

Oncogene

YTHDC2 inhibits the resistance of lung cancer to EGFR-TKI through cuproptosis. [Abstract]

2025 Dec 16. PMID: 41402633

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (344.45 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

6.8889 mL

34.4447 mL

68.8895 mL

5 mM

1.3778 mL

6.8889 mL

13.7779 mL

10 mM

0.6889 mL

3.4445 mL

6.8889 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (17.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (17.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (17.22 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (949 KB)
- English - EN (949 KB)
- Français - FR (949 KB)
- Deutsch - DE (949 KB)
- Norwegian - NO (949 KB)
- Español - ES (949 KB)
- Swedish - SV (949 KB)
- Italian - IT (949 KB)
- Korean - KR (949 KB)
- Portuguese - PT (949 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lawung R, et.al. Repositioning of 8-hydroxyquinoline derivatives as a new promising candidate for combating multidrug resistant Neisseria gonorrhoeae. EXCLI J. 2018 Aug 23;17:840-846. [Content Brief]

[2]. 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells. J Biol Inorg Chem. 2010 Feb;15(2):259-69. [Content Brief]

[3]. Zhai S, et.al. Tumor cellular proteasome inhibition and growth suppression by [Content Brief]

[4]. Hamoud MA, et.al. Effects of quinoline and 8-hydroxyquinoline on mouse bone marrow erythrocytes as measured by the micronucleus assay. Teratog Carcinog Mutagen. 1989;9(2):111-8. [Content Brief]

[5]. Searle CE. The selective depigmenting action of 8-hydroxyquinoline on hair growth in the mouse. Br J Dermatol. 1972 May;86(5):472-80. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	6.8889 mL	34.4447 mL	68.8895 mL	172.2237 mL
	5 mM	1.3778 mL	6.8889 mL	13.7779 mL	34.4447 mL
	10 mM	0.6889 mL	3.4445 mL	6.8889 mL	17.2224 mL
	15 mM	0.4593 mL	2.2963 mL	4.5926 mL	11.4816 mL
	20 mM	0.3444 mL	1.7222 mL	3.4445 mL	8.6112 mL
	25 mM	0.2756 mL	1.3778 mL	2.7556 mL	6.8889 mL
	30 mM	0.2296 mL	1.1482 mL	2.2963 mL	5.7408 mL
	40 mM	0.1722 mL	0.8611 mL	1.7222 mL	4.3056 mL
	50 mM	0.1378 mL	0.6889 mL	1.3778 mL	3.4445 mL
	60 mM	0.1148 mL	0.5741 mL	1.1482 mL	2.8704 mL
	80 mM	0.0861 mL	0.4306 mL	0.8611 mL	2.1528 mL
	100 mM	0.0689 mL	0.3444 mL	0.6889 mL	1.7222 mL

Keywords

8-Hydroxyquinoline

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

8-Hydroxyquinoline

Antibacterial Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Breast Cancer Compound Library

FDA-Approved Anticancer Drug Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Environmental Pollutant Compound Library

Drug Fragment Library

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) 8-Hydroxyquinoline

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

8-Hydroxyquinoline

Antibacterial Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Breast Cancer Compound Library

FDA-Approved Anticancer Drug Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Environmental Pollutant Compound Library

Drug Fragment Library

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) 8-Hydroxyquinoline

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

8-Hydroxyquinoline Related Classifications

HY-B1005 Related Classifications